00690 UNI-BIO GROUP
- 0.074
- -0.002-2.63%
UNI-BIO GROUP News
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
聯康生物科技集團：年報2023
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Liankang Biotechnology Group (00690) announced its 2023 annual results. Revenue reached a record high, with profit reaching HK$70.9 million, a significant increase of 84.04% over the previous year
According to the Zhitong Finance App, Liankang Biotechnology Group (00690) announced its annual results for the year ended December 31, 2023. The Group's revenue reached a record high, reaching approximately HK$484.7 million, an increase of 10.1% year-on-year. The sales performance of Pina Generic Gin Peptides was exceptional, with year-on-year increases of 15.0% and 9.54%, respectively. Profit during the year reached approximately HK$70.9 million, a significant year-on-year increase of 84.04%, making it an important milestone for a research biopharmaceutical company. General and administrative expenses as a percentage of revenue decreased from 10.7% to 9.8% during the year due to the Group's continued internal growth
UNI-BIO GROUP: ANNOUNCEMENT OF FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Hong Kong pharmaceutical stocks bucked the trend, and Pharmacovigilance led their sector. Is the “Biosafety Act” or a biological variable?
① Why is the market paying attention to the Biosafety Act? ② How has Yao Ming Kangde performed recently?
Liankang Biotechnology Group (00690.HK) will hold a board meeting on March 27 to approve the annual results
Gelonghui March 15 | Liankang Biotechnology Group (00690.HK) issued an announcement. The company's board of directors meeting will be held on March 27, 2024 to review and approve the Group's annual results and announcements for the year ended December 31, 2023, and consider the proposal to pay a final dividend (if any).
UNI-BIO GROUP: DATE OF BOARD MEETING
Yao Ming Kangde was removed from BIO membership! Where will the domestic innovative drug sector go?
The path to the rise of innovative drugs doesn't seem easy!
Not only is Daimo bullish, but Xiaoma has taken steps to increase its holdings of the drug Ming Kangde. Major international banks are turning one after another, and the Hong Kong stock pharmaceutical industry is welcoming a “crouching and leap”?
① Hong Kong stocks of Innovative Pharmaceuticals soared at the end of yesterday. Collumbotai Biotech B rose 14.9%; Rongchang Biotech rose 14.8%; Connoya B rose 12.8%; ② Although “Yao Mao” Pharmaceutical Kangde Hong Kong shares closed down 1.16%, the decline narrowed sharply at the end of the session, and J.P. Morgan increased its holdings by 1.654 million shares, or HK$77.68 million.
Express News | China Artificial Intelligence Industry Development Alliance plans to initiate the establishment of a “Biomedical Industry Working Group”
What is the biggest highlight of medicine this year? The new version of the basic drug catalogue expands traditional Chinese medicine and pediatric medicine and is expected to usher in benefits|Traditional Chinese Medicine 2024 outlook
Finance Association, Feb. 29 (Reporter Zhang Liangde) “The biggest highlight of the pharmaceutical industry this year is the expansion of the new version of the basic drug catalogue.
Uni-Bio Science's Profit to Climb in 2023
Uni-Bio Science Group (HKG:0690) expects to book a profit attributable to the owners of not less than HK$60 million for the financial year 2023, higher than HK$38.5 million a year earlier. The biotech
Liankang Biotechnology: Earnings are expected to increase last year
Gelonghui, Feb. 14 | Liankang Biotechnology Group (0690.HK) announced that it is expected that the profit attributable to parent company owners for the year ended the end of December last year will not be less than HK$60 million, with a profit of HK$38.51 million for the same period last year. The company said that the expected increase is mainly due to sales revenue increasing by no less than 10%; continuing to optimize and control production costs; and achieving CMO revenue of more than HK$9 million, with annual revenue growth of not less than 2 times.
UNI-BIO GROUP: POSITIVE PROFIT ALERT
Liankang Biotechnology Group (00690) cancelled 201 million shares repurchased
Liankang Biotechnology Group (00690) announced that on February 7, 2024, the company cancelled 201 million...
Hong Kong Stock Concept Tracking | Pharmaceutical companies' pricing is being loosened? The innovative drug sector is expected to usher in a beta market (with concept stocks)
On February 5, the National Health Insurance Administration issued a letter to relevant industry associations seeking comments on the “Notice on Establishing a Initial Price Formation Mechanism for Newly Launched Chemicals to Encourage High-Quality Innovation (Draft for Comments)”.
Analysis
Price Target
No Data
